Medicus Pharma Ltd. (MDCX)

Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

Wall Street sets positive tone as investors digest hotter inflation data

Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Dow falls as Treasury yields jump to highest level since 2023

Wall Street slips for a third straight day as oil and yields climb

Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

Medicus Pharma advances pipeline during Q2 with key milestones

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SK Hynix backed by Wedbush as memory undersupply persists

Medicus Pharma CMO to lead Antev's Teverelix clinical programme

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom